Cite

HARVARD Citation

    Wu, J. et al. (2021). Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. Journal of dermatological treatment. pp. 693-700. [Online]. 
  
Back to record